罗格列酮对慢性胰腺炎大鼠肝细胞Glut2表达的调节

Regulation of rosiglitazone on hepatocellular glucose transporter-2expression in experimental chronic pancreatitis rat

目的:建立慢性胰腺炎(chronic pancreatitis,CP)大鼠模型,观察其空腹血糖(fasting blood glucose,FBG)、血清胰岛素水平、以及肝脏葡萄糖运载体-2(glucose transporter-2,Glut2)表达的改变,探讨罗格列酮的改善和调节作用。方法:用油酸经胰胆管插管灌注的方法诱导CP,将6周后成模大鼠随机分成模型组和治疗组,治疗组以罗格列酮灌胃治疗7 d,模型组以蒸馏水灌胃7 d。对照组以同样方法经胰胆管插管灌注生理盐水,6周后蒸馏水灌胃对照。试验结束时测定FBG和血清胰岛素水平,Westernblots法测定各组大鼠肝细胞Glut2表达的改变。结果:模型组、治疗组和对照组的FBG分别为(8.0±1.50)、(6.4±0.76)和(5.8±0.40)mmol/L;血清胰岛素分别为(6.7±0.79)、(7.3±0.78)和(8.7±0.70)μIU/ml;Glut2条带的光密度积分值分别为(28.28±2.36)、(32.47±2.16)和(39.25±3.08),模型组肝细胞Glut2表达较对照组降低27.95%,治疗组肝细胞Glut2表达较模型组上调14.82%。结论:模型组空腹血糖较对照组明显升高(P<0.05),胰导素水平和肝细胞Glut2表达较对照组有明显降低(P<0.05);治疗组FBG明显降低(P<0.05),Glut2表达较模型组有明显的上调(P<0.05)。罗格列酮能够增加CP大鼠Glut2在肝细胞表面的数目,改善胰岛素信号转导,降低CP大鼠的空腹血糖。

OBJECTIVE To establish rat model of chronic pancreatitis, then to observe the changes of its FBG, serum insulin level and expression of hepatocellular glucose transporter - 2, so as to discuss the improvement and regulating mechanism of Rosiglitazone. METHODS Chronic pancreatitis rats were induced by oleic acid injection into the pancreatic duct. Model rats were divided into model group and treated group. Treated rats were administered of Rosiglitazone and model rats were given distilled water for 7 days. The control rats were injected NS into pancreatic duct and then given water the same as model rats for 7 days after 6 weeks. At the end of experiments, FBG and serum insulin level were detected and the expression of Glut2 was observed by westernblots. RESULTS FBG （ mmol/L） showed： model （ 8.0 ± 1.50 ） , treatment （ 6.4 ± 0.76 ） and control （ 5.8 ± 0.40 ）. Serum insulin showed ： model （ 6.7 ± 0.79 ） , treatment （ 7.3 ± 0.78 ） and control （ 8.7 ± 0.70 ）. Optical density score of Glut2 showed ： model （28.28 ±2.36） , treatment （ 32.47 ± 2.16） and control （ 39.25 ± 3.08 ）. Expression of hepatocellular Glut2 in model rats de- creased 27.95% than control rats. Expression of hepatocellular Glut2 in treated rats increased 14.82% than model rats. CON- CLUSION Compared with control rats, model rats showed FBG remarkable increase （P 〈 0.05） , while decrease of insulin level and Glut2 expression （ P 〈 0.05 ） ; Rats treated by Rosiglitazone demonstrated FBG decrease and up - regulation of hepatocellular Glut2 compared with model rats. Rosiglitazone may increase the number of Glut2 on the CP hepatocellular surface, improve insulin signal transduction and decrease FBG of CP rats.